From WikiProjectMed
Jump to navigation Jump to search
Combination of
TezacaftorCFTR corrector
IvacaftorCFTR potentiator
Trade namesSymkevi, Symdeko
Clinical data
Main usesCystic fibrosis[1]
Side effectsNausea, headache, diarrhea, dizziness[1]
InteractionsCYP3A inhibitors[2]
  • AU: B3
External links
US NLMTezacaftor/ivacaftor

Tezacaftor/ivacaftor, sold under the brand name Symdeko, is a combination medication of tezacaftor and ivacaftor used to treat cystic fibrosis.[1] It is only used in people with specific mutations.[1] It is taken by mouth.[1]

Common side effects include nausea, headache, diarrhea, and dizziness.[1] Other side effects may include liver problems and cataracts.[1][3] In those with significant liver problems a lower dose may be required.[3] Tezacaftor increases the number of CFTR while ivacaftor increases the ability of CFTR.[2]

The combination was approved for medical use in the United States and Europe in 2018.[3][2] In the United States it costs about 304,000 USD per year as of 2021.[4] It became available in the United Kingdom in 2020 at a cost of about £82,000 per year.[5]

Medical use

It may be used in people over the age of 5.[2]


A combination tablet of tezacaftor 100 mg with ivacaftor 150 mg is taken in the am while a ivacaftor 150 mg tablet is taken in the evening.[3]


  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Tezacaftor and Ivacaftor Monograph for Professionals". Drugs.com. Retrieved 8 October 2021.
  2. 2.0 2.1 2.2 2.3 "Symkevi". Retrieved 8 October 2021.
  3. 3.0 3.1 3.2 3.3 "SYMDEKO™ (tezacaftor/ivacaftor) tablets; (ivacaftor) tablets, for oral use" (PDF). Retrieved 8 October 2021.
  4. "Symdeko Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 8 October 2021.
  5. "Tezacaftor + ivacaftor". SPS - Specialist Pharmacy Service. 29 December 2015. Retrieved 8 October 2021.